OVAS vs. CTXR, RPTX, EBS, KPTI, GLYC, RLMD, INCR, PDSB, COYA, and NVCT
Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include Citius Pharmaceuticals (CTXR), Repare Therapeutics (RPTX), Emergent BioSolutions (EBS), Karyopharm Therapeutics (KPTI), GlycoMimetics (GLYC), Relmada Therapeutics (RLMD), InterCure (INCR), PDS Biotechnology (PDSB), Coya Therapeutics (COYA), and Nuvectis Pharma (NVCT). These companies are all part of the "medical" sector.
Citius Pharmaceuticals (NASDAQ:CTXR) and OvaScience (NASDAQ:OVAS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
In the previous week, Citius Pharmaceuticals had 2 more articles in the media than OvaScience. MarketBeat recorded 2 mentions for Citius Pharmaceuticals and 0 mentions for OvaScience. Citius Pharmaceuticals' average media sentiment score of 0.00 beat OvaScience's score of -0.50 indicating that OvaScience is being referred to more favorably in the news media.
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 22.5% of OvaScience shares are held by institutional investors. 15.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
OvaScience received 68 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 63.87% of users gave OvaScience an outperform vote while only 62.05% of users gave Citius Pharmaceuticals an outperform vote.
Citius Pharmaceuticals has higher earnings, but lower revenue than OvaScience.
Citius Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 501.68%. Given OvaScience's higher possible upside, research analysts clearly believe Citius Pharmaceuticals is more favorable than OvaScience.
Citius Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500.
Citius Pharmaceuticals has a net margin of 0.00% compared to Citius Pharmaceuticals' net margin of -10,128.37%. OvaScience's return on equity of -41.63% beat Citius Pharmaceuticals' return on equity.
Summary
Citius Pharmaceuticals beats OvaScience on 8 of the 14 factors compared between the two stocks.
Get OvaScience News Delivered to You Automatically
Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OvaScience Competitors List
Related Companies and Tools
